Can we use circulating biomarkers to monitor bone turnover in CKD haemodialysis patients? Hypotheses and facts

Nephrology Dialysis Transplantation

Volumn 29, Issue 5, 2014, Pages 997-1004

  Delanaye, Pierre ^a   Souberbielle, Jean Claude ^b   Lafage Proust, Marie Hélène ^c   Jean, Guillaume ^d   Cavalier, Etienne ^a  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b INSERM   (France)

^c UNIVERSITÉ DE LYON   (France)

^d NephroCare Tassin Charcot ^*  (France)

Author keywords

biomarkers; bone turnover; parathormone

Indexed keywords

ALKALINE PHOSPHATASE; BIOLOGICAL MARKER; PARATHYROID HORMONE;

ARTICLE; BONE BIOPSY; BONE MASS; BONE MINERALIZATION; BONE TURNOVER; CHRONIC KIDNEY DISEASE; CLINICAL PRACTICE; DISEASE ASSOCIATION; GOLD STANDARD; HEMODIALYSIS PATIENT; HUMAN; PARATHYROID HORMONE BLOOD LEVEL; PATHOPHYSIOLOGY; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RENAL OSTEODYSTROPHY; RISK FACTOR;

BIOMARKERS; BONE TURNOVER; PARATHORMONE;

BIOLOGICAL MARKERS; BONE AND BONES; BONE DENSITY; BONE DISEASES; HUMANS; PROGNOSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC;

EID: 84899871634     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft275     Document Type: Article

References (73)

1. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-S130
2. Mac Way F, Lessard M, Lafage-Proust MH. Pathophysiology of chronic kidney disease-mineral and bone disorder. Joint Bone Spine 2012; 79: 544-549
3. Jadoul M, Albert JM, Akiba T et al. Incidence and risk factors for hip or other bone fractures among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2006; 70: 1358-1366
4. Stevens LA, Djurdjev O, Cardew S et al. Calcium, phosphate, and parathyroid hormone levels in combination and as a function of dialysis duration predict mortality: evidence for the complexity of the association between mineral metabolism and outcomes. J Am Soc Nephrol 2004; 15: 770-779
5. Block GA, Klassen PS, Lazarus JM et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15: 2208-2218
6. Bervoets AR, Spasovski GB, Behets GJ et al. Useful biochemical markers for diagnosing renal osteodystrophy in predialysis end-stage renal failure patients. Am J Kidney Dis 2003; 41: 997-1007
7. Coen G, Ballanti P, Bonucci E et al. Bone markers in the diagnosis of low turnover osteodystrophy in haemodialysis patients. Nephrol Dial Transplant 1998; 13: 2294-2302
8. Monier-Faugere MC, Geng Z, Mawad H et al. Improved assessment of bone turnover by the PTH-(1-84)/large C-PTH fragments ratio in ESRD patients. Kidney Int 2001; 60: 1460-1468
9. Urena P, Hruby M, Ferreira A et al. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol 1996; 7: 506-512
10. Cavalier E, Delanaye P, Moranne O. Variability of new bone mineral metabolism markers in patients treated with maintenance hemodialysis: implications for clinical decision making. Am J Kidney Dis 2013; 61: 847-848
11. Ricos C, Alvarez V, Cava F et al. Current databases on biological variation: pros, cons and progress. Scand J Clin Lab Invest 1999; 59: 491-500
12. Malluche HH, Mawad HW, Monier-Faugere MC. Renal osteodystrophy in the first decade of the new millennium: analysis of 630 bone biopsies in black and white patients. J Bone Miner Res 2011; 26: 1368-1376
13. Kovesdy CP, Quarles LD. Fibroblast growth factor-23: what we know, what we don't know, and what we need to know. Nephrol Dial Transplant 2013. [Epub ahead of print]
14. Pelletier S, Dubourg L, Carlier MC et al. The relation between renal function and serum sclerostin in adult patients with CKD. Clin J Am Soc Nephrol 2013; 8: 819-823
15. Kalantar-Zadeh K, Kuwae N, Regidor DL et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006; 70: 771-780
16. Coco M, Rush H. Increased incidence of hip fractures in dialysis patients with low serum parathyroid hormone. Am J Kidney Dis 2000; 36: 1115-1121
17. Nussbaum SR, Zahradnik RJ, Lavigne JR et al. Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia. Clin Chem 1987; 33: 1364-1367
18. Slatopolsky E, Finch J, Clay P et al. A novel mechanism for skeletal resistance in uremia. Kidney Int 2000; 58: 753-761
19. Souberbielle JC, Boutten A, Carlier MC et al. Inter-method variability in PTH measurement: implication for the care of CKD patients. Kidney Int 2006; 70: 345-350
20. Gao P, Scheibel S, D'Amour P et al. Development of a novel immunora-diometric assay exclusively for biologically active whole parathyroid hormone 1-84: implications for improvement of accurate assessment of parathyroid function. J Bone Miner Res 2001; 16: 605-614
21. Coen G, Bonucci E, Ballanti P et al. PTH 1-84 and PTH '7-84' in the noninvasive diagnosis of renal bone disease. Am J Kidney Dis 2002; 40: 348-354
22. Lehmann G, Stein G, Huller M et al. Specific measurement of PTH (1-84) in various forms of renal osteodystrophy (ROD) as assessed by bone histo-morphometry. Kidney Int 2005; 68: 1206-1214
23. Salusky IB, Goodman WG, Kuizon BD et al. Similar predictive value of bone turnover using first-and second-generation immunometric PTH assays in pediatric patients treated with peritoneal dialysis. Kidney Int 2003; 63: 1801-1808
24. Sawaya BP, Butros R, Naqvi S et al. Differences in bone turnover and intact PTH levels between African American and Caucasian patients with end-stage renal disease. Kidney Int 2003; 64: 737-742
25. Cosman F, Morgan DC, Nieves JW et al. Resistance to bone resorbing effects of PTH in black women. J Bone Miner Res 1997; 12: 958-966
26. Melamed ML, Eustace JA, Plantinga LC et al. Third-generation parathyroid hormone assays and all-cause mortality in incident dialysis patients: the CHOICE study. Nephrol Dial Transplant 2008; 23: 1650-1658
27. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201
28. Barreto FC, Barreto DV, Moyses RM et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients. Kidney Int 2008; 73: 771-777
29. Cavalier E, Delanaye P, Vranken L et al. Interpretation of serum PTH concentrations with different kits in dialysis patients according to the KDIGO guidelines: importance of the reference (normal) values. Nephrol Dial Transplant 2012; 27: 1950-1956
30. Clinical practice guideline for the management of secondary hyperparathyroidism in chronic dialysis patients. Ther Apher Dial 2008; 12: 514-525
31. Qunibi W, Kalantar-Zadeh K. Target levels for serum phosphorus and parathyroid hormone. Semin Dial 2011; 24:29-33
32. Gardham C, Stevens PE, Delaney MP et al. Variability of parathyroid hormone and other markers of bone mineral metabolism in patients receiving hemodialysis. Clin J Am Soc Nephrol 2010; 5: 1261-1267
33. Harris H. The human alkaline phosphatases: what we know and what we don't know. Clin Chim Acta 1990; 186: 133-150
34. Fletcher S, Jones RG, Rayner HC et al. Assessment of renal osteodystrophy in dialysis patients: use of bone alkaline phosphatase, bone mineral density and parathyroid ultrasound in comparison with bone histology. Nephron 1997; 75: 412-419
35. Delanaye P, Dubois BE, Jouret F et al. Parathormone and bone-specific alkaline phosphatase for the follow-up of bone turnover in hemodialysis patients: is it so simple? Clin Chim Acta 2013; 417: 35-38
36. Moore C, Yee J, Malluche H et al. Relationship between bone histology and markers of bone and mineral metabolism in African-American hemodialysis patients. Clin J Am Soc Nephrol 2009; 4: 1484-1493
37. Jean G, Souberbielle JC, Granjon S et al. Bone biomarkers in haemodialy-sis patients: Bone alkaline phosphatase or (3-Crosslaps?. Nephrol Ther 2013; 9: 154-159
38. Jean G, Souberbielle JC, Zaoui E et al. Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem 2012; 45: 436-439
39. Coen G, Ballanti P, Balducci A et al. Serum osteoprotegerin and renal osteodystrophy. Nephrol Dial Transplant 2002; 17: 233-238
40. Hutchison AJ, Whitehouse RW, Boulton HF et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int 1993; 44: 1071-1077
41. Cavalier E, Delanaye P, Collette J et al. Evaluation of different bone markers in hemodialyzed patients. Clin Chim Acta 2006; 371: 107-111
42. Jarava C, Armas JR, Salgueira M et al. Bone alkaline phosphatase isoenzyme in renal osteodystrophy. Nephrol Dial Transplant 1996; 11(Suppl. 3): 43-46
43. Couttenye MM, D'Haese PC, Van Hoof VO et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients. Nephrol Dial Transplant 1996; 11: 1065-1072
44. Lehmann G, Ott U, Kaemmerer D et al. Bone histomorphometry and biochemical markers of bone turnover in patients with chronic kidney disease Stages 3-5. Clin Nephrol 2008; 70: 296-305
45. Iimori S, Mori Y, Akita W et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients-A single-center cohort study. Nephrol Dial Transplant 2012; 27: 345-351
46. Beddhu S, Ma X, Baird B et al. Serum alkaline phosphatase and mortality in African Americans with chronic kidney disease. Clin J Am Soc Nephrol 2009; 4: 1805-1810
47. Regidor DL, Kovesdy CP, Mehrotra R et al. Serum alkaline phosphatase predicts mortality among maintenance hemodialysis patients. J Am Soc Nephrol 2008; 19: 2193-2203
48. Blayney MJ, Pisoni RL, Bragg-Gresham JL et al. High alkaline phosphatase levels in hemodialysis patients are associated with higher risk of hospitaliza-tion and death. Kidney Int 2008; 74: 655-663
49. Kovesdy CP, Ureche V, Lu JL et al. Outcome predictability of serum alkaline phosphatase in men with pre-dialysis CKD. Nephrol Dial Transplant 2010; 25: 3003-3011
50. Kobayashi I, Shidara K, Okuno S et al. Higher serum bone alkaline phos-phatase as a predictor of mortality in male hemodialysis patients. Life Sci 2012; 90: 212-218
51. Drechsler C, Verduijn M, Pilz S et al. Bone alkaline phosphatase and mortality in dialysis patients. Clin J Am Soc Nephrol 2011; 6: 1752-1759
52. Cavalier E, Rozet E, Carlisi A et al. Analytical validation of serum bone alkaline phosphatase (BAP OSTASE) on Liaison. Clin Chem Lab Med 2010; 48: 67-72
53. Cavalier E, Delanaye P, Carlisi A et al. Stability of intact parathyroid hormone in samples from hemodialysis patients. Kidney Int 2007; 72: 370-372
54. Sardiwal S, Gardham C, Coleman AE et al. Bone-specific alkaline phos-phatase concentrations are less variable than those of parathyroid hormone in stable hemodialysis patients. Kidney Int 2012; 82: 100-105
55. Garrett G, Sardiwal S, Lamb EJ et al. PTH-A Particularly Tricky Hormone: Why Measure It at All in Kidney Patients?. Clin J Am Soc Nephrol 2012; 8: 299-312
56. Sanchez C, Lopez-Barea F, Sanchez-Cabezudo J et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004; 19: 1587-1593
57. Jean G, Chazot C, Charra B. 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin Nephrol 2007; 68: 63-64
58. Vasikaran S, Eastell R, Bruyere O et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011; 22: 391-420
59. Nakasato YR, Janckila AJ, Halleen JM et al. Clinical significance of immu-noassays for type-5 tartrate-resistant acid phosphatase. Clin Chem 1999; 45: 2150-2157
60. Halleen JM, Alatalo SL, Suominen H et al. Tartrate-resistant acid phos-phatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000; 15: 1337-1345
61. Shidara K, Inaba M, Okuno S et al. Serum levels of TRAP5b, a new bone resorption marker unaffected by renal dysfunction, as a useful marker of cortical bone loss in hemodialysis patients. Calcif Tissue Int 2008; 82: 278-287
62. Chu P, Chao TY, Lin YF et al. Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 2003; 41: 1052-1059
63. Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type I procollagen (PINP) in serum. Clin Biochem 2012; 45: 920-927
64. Melkko J, Hellevik T, Risteli L et al. Clearance of NH2-terminal propep-tides of types I and III procollagen is a physiological function of the scavenger receptor in liver endothelial cells. J Exp Med 1994; 179: 405-412
65. Ueda M, Inaba M, Okuno S et al. Clinical usefulness of the serum N-ter-minal propeptide of type I collagen as a marker of bone formation in hemodialysis patients. Am J Kidney Dis 2002; 40: 802-809
66. Kleerekoper M. Biochemical markers of bone remodeling. Am J Med Sci 1996; 312: 270-277
67. Garnero P, Hausherr E, Chapuy MC et al. Markers of bone resorption predict hip fracture in elderly women: the EPIDOS Prospective Study. J Bone Miner Res 1996; 11: 1531-1538
68. Qvist P, Christgau S, Pedersen BJ et al. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone 2002; 31: 57-61
69. Reichel H, Roth HJ, Schmidt-Gayk H. Evaluation of serum beta-carboxy-terminal cross-linking telopeptide of type I collagen as marker of bone re-sorption in chronic hemodialysis patients. Nephron Clin Pract 2004; 98: c112-c118
70. Okabe R, Nakatsuka K, Inaba M et al. Clinical evaluation of the Elecsys beta-CrossLaps serum assay, a new assay for degradation products of type I collagen C-tlopeptides. Clin Chem 2001; 47: 1410-1414
71. Malyszko J, Wolczynski S, Zbroch E et al. Brzosko S, Malyszko J, Mysli-wiec M. Serum crosslaps correlations with serum ICTP and urine DPD in hemodialyzed and peritoneally dialyzed patients. Nephron 2001; 87: 283-285
72. Negri AL, Quiroga MA, Bravo M et al. Serum crosslaps as bone resorption marker in peritoneal dialysis. Perit Dial Int 2002; 22: 628-630
73. Graf S, Bohner J, Hertel A. Evaluation of Beta-CrossLaps in haemodialysis patients. Nephrol Dial Transplant 2013; 18(Suppl. 4): 407